Outlook Therapeutics ties executive pay to FDA outcome

Outlook Therapeutics, Inc. approved new equity and cash incentives for its chief executive and chief financial officers tied to potential FDA approval of ONS-5010 (bevacizumab-vikg).

Rhea-AI Filing Summary

Outlook Therapeutics, Inc. approved new equity and cash incentives for its chief executive and chief financial officers tied to potential FDA approval of ONS-5010 (bevacizumab-vikg). The awards recognize their efforts during 2025 and 2026 advancing the Biologics License Application through FDA review and appeal processes.

The chief executive officer received options to purchase 100,000 shares and the chief financial officer 210,078 shares under the 2024 Equity Incentive Plan, all at an exercise price of $1.4304 per share, vesting on July 21, 2027 subject to continued service. They also received cash bonus opportunities of $420,000 and $200,000, respectively, which will be earned and payable only if, on or before July 31, 2026, the FDA approves ONS-5010 and issues a favorable decision on the Biologics License Application and each executive remains in service through payment.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

CEO stock options: 100,000 options CFO stock options: 210,078 options Option exercise price: $1.4304 per share +4 more

7 metrics

CEO stock options 100,000 options Options to purchase common stock granted July 21, 2026 to the chief executive officer

CFO stock options 210,078 options Options to purchase common stock granted July 21, 2026 to the chief financial officer

Option exercise price $1.4304 per share Exercise price for options granted under the 2024 Equity Incentive Plan

Option vesting date July 21, 2027 Date on which the granted options vest and become exercisable, subject to continued service

CEO bonus opportunity $420,000 Cash bonus amount contingent on FDA approval of ONS-5010 by July 31, 2026

CFO bonus opportunity $200,000 Cash bonus amount contingent on FDA approval of ONS-5010 by July 31, 2026

Bonus condition deadline July 31, 2026 Latest date by which FDA must approve ONS-5010 for bonuses to be earned

Key Terms

Biologics License Application, bevacizumab-vikg, 2024 Equity Incentive Plan, exercise price

4 terms

Biologics License Application regulatory

"advancing the Company’s Biologics License Application (the “BLA”) for ONS-5010"

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

bevacizumab-vikg medical

"the Company’s BLA for ONS-5010 (bevacizumab-vikg) through the review"

Bevacizumab-vikg is a biosimilar version of a cancer-fighting monoclonal antibody that blocks a protein tumors use to grow blood vessels, effectively starving them of nutrients. For investors, it matters because biosimilars offer a lower-cost alternative to an established biologic drug, which can capture market share, compress prices, and change revenue forecasts for companies selling the original drug or competing copies — think of it as a generic equivalent for a complex, high-priced medicine.

2024 Equity Incentive Plan financial

"granted pursuant to the Company’s 2024 Equity Incentive Plan (the “2024 Plan”)"

exercise price financial

"with an exercise price of $1.4304 per share, the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive compensation actions did Outlook Therapeutics (OTLK) take on July 21, 2026?

Outlook Therapeutics approved new stock option grants and conditional cash bonus opportunities for its CEO and CFO. The package includes options on 100,000 and 210,078 shares and potential cash bonuses of $420,000 and $200,000, tied to possible FDA approval of ONS-5010.

What stock options were granted to Outlook Therapeutics (OTLK) executives and at what price?

The CEO received options to purchase 100,000 shares and the CFO 210,078 shares of common stock. All options were granted under the 2024 Equity Incentive Plan with an exercise price of $1.4304 per share and will vest on July 21, 2027, subject to continued service.

What are the cash bonus amounts and conditions for Outlook Therapeutics (OTLK) CEO and CFO?

The CEO was awarded a cash bonus opportunity of $420,000 and the CFO $200,000. Each bonus will be earned and payable only if, on or before July 31, 2026, the FDA approves ONS-5010 and issues a favorable decision on the company’s Biologics License Application, with continued service required.

How is FDA approval of ONS-5010 linked to Outlook Therapeutics (OTLK) executive pay?

Both executives’ cash bonuses are contingent on FDA approval of ONS-5010 (bevacizumab-vikg) and a favorable decision on the Biologics License Application by July 31, 2026. Without this regulatory outcome, the bonuses will not be earned or paid.

When do the new Outlook Therapeutics (OTLK) executive stock options vest?

All option awards granted to the CEO and CFO vest and become exercisable on July 21, 2027. Vesting is subject to each executive’s continued service with Outlook Therapeutics through that date, aligning the incentive with ongoing tenure at the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/24/2026 - 06:02 AM Accepted by SEC EDGAR 07/23/2026 - 07:54 PM Learn about SEC filing dates

false 0001649989 0001649989 2026-07-21 2026-07-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): July 21, 2026

Outlook Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37759	38-3982704
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

111 S. Wood Avenue, Unit #100 Iselin, New Jersey	08830
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (609) 619-3990

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock		OTLK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 21, 2026, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Outlook Therapeutics, Inc. (the “Company”) approved the grant of stock options to purchase shares of the Company’s common stock to the Company’s named executive officers as follows: Robert C. Jahr, the Company’s Chief Executive Officer – 100,000 options and Lawrence A. Kenyon, the Company’s Chief Financial Officer – 210,078 options (collectively, the “Option Awards”). The Option Awards were granted pursuant to the Company’s 2024 Equity Incentive Plan (the “2024 Plan”) and the Company’s standard form of stock option agreement thereunder, with an exercise price of $1.4304 per share, the closing price of the Company’s common stock on The Nasdaq Capital Market on the grant date. The Option Awards will vest and become exercisable on July 21, 2027, subject to the applicable officer’s continuing service with the Company through such vesting date. The Option Awards were granted in recognition of Mr. Jahr’s and Mr. Kenyon’s efforts and contributions during 2025 and 2026 in advancing the Company’s Biologics License Application (the “BLA”) for ONS-5010 (bevacizumab-vikg) through the review and appeal processes with the U.S. Food and Drug Administration (the “FDA”).

In addition, on July 21, 2026, the Compensation Committee approved the award of cash bonus opportunities to Mr. Jahr and Mr. Kenyon in the amounts of $420,000 and $200,000, respectively (the “Bonus” and together, the “Bonuses”). Each Bonus will be earned and become payable only in the event that, on or prior to July 31, 2026, the FDA approves ONS-5010 (bevacizumab-vikg) and renders a favorable decision with respect to the Company’s BLA. The Compensation Committee awarded the Bonuses in recognition of Mr. Jahr and Mr. Kenyon’s contributions to the advancement of the ONS-5010 (bevacizumab-vikg) BLA and the Company’s non-payment of annual bonuses for their 2025 service. Each Bonus, if earned, will be paid, less applicable deductions and withholdings, subject to the applicable officer’s continuing service with the Company through the date of payment.

The foregoing description of the Option Awards does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the 2024 Plan and the form of stock option agreement thereunder, each of which has been previously filed with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Outlook Therapeutics, Inc.
Date: July 23, 2026	By:	/s/ Lawrence A. Kenyon
		Lawrence A. Kenyon
		Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.0 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.9 KB